{
    "ticker": "CERT",
    "name": "Certara, Inc.",
    "description": "Certara, Inc. is a leading global provider of software and technology-enabled services that optimize drug development and regulatory approval. Founded in 2008, the company integrates scientific knowledge and advanced modeling techniques to facilitate the development of safe and effective therapeutics. Certara\u2019s innovative platform harnesses the power of pharmacokinetics, pharmacodynamics, and other advanced quantitative methods to guide drug discovery and development processes. The company serves a broad range of clients, including biopharmaceutical companies, regulatory agencies, and academic institutions, providing solutions that enable them to make informed decisions throughout the drug development lifecycle. Certara's mission is to improve patient health by providing the insights that help researchers and developers bring new therapies to market more efficiently. With a commitment to innovation and excellence, Certara is at the forefront of the growing field of model-informed drug development, helping to reduce costs and timelines associated with bringing new drugs to market. The company's extensive portfolio includes offerings in areas such as clinical pharmacology, regulatory science, and real-world evidence, all designed to enhance the drug development process and ensure compliance with regulatory standards.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology",
        "Healthcare Technology"
    ],
    "headquarters": "Princeton, New Jersey, USA",
    "founded": "2008",
    "website": "https://www.certara.com",
    "ceo": "William F. Feeherry",
    "social_media": {
        "twitter": "https://twitter.com/Certara",
        "linkedin": "https://www.linkedin.com/company/certara"
    },
    "investor_relations": "https://investors.certara.com",
    "key_executives": [
        {
            "name": "William F. Feeherry",
            "position": "CEO"
        },
        {
            "name": "Sandeep G. Ghosh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Software Solutions",
            "products": [
                "Phoenix",
                "Simcyp",
                "DILIsym"
            ]
        },
        {
            "category": "Consulting Services",
            "products": [
                "Regulatory Consulting",
                "Clinical Pharmacology Consulting"
            ]
        }
    ],
    "seo": {
        "meta_title": "Certara, Inc. | Drug Development Optimization Solutions",
        "meta_description": "Certara, Inc. is a global leader in software and services for drug development. Discover how Certara enhances drug development processes with innovative technology.",
        "keywords": [
            "Certara",
            "Drug Development",
            "Pharmacokinetics",
            "Pharmacodynamics",
            "Biopharmaceutical",
            "Healthcare Technology"
        ]
    },
    "faq": [
        {
            "question": "What does Certara do?",
            "answer": "Certara specializes in software and technology-enabled services that optimize drug development processes."
        },
        {
            "question": "Who is the CEO of Certara?",
            "answer": "William F. Feeherry is the CEO of Certara, Inc."
        },
        {
            "question": "Where is Certara headquartered?",
            "answer": "Certara is headquartered in Princeton, New Jersey, USA."
        },
        {
            "question": "What are the main products offered by Certara?",
            "answer": "Certara's main products include Phoenix, Simcyp, and DILIsym, along with various consulting services."
        },
        {
            "question": "When was Certara founded?",
            "answer": "Certara was founded in 2008."
        }
    ],
    "competitors": [
        "SRPT",
        "MLNX",
        "PTCT",
        "NTRA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}